CL2014003286A1 - Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica. - Google Patents

Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica.

Info

Publication number
CL2014003286A1
CL2014003286A1 CL2014003286A CL2014003286A CL2014003286A1 CL 2014003286 A1 CL2014003286 A1 CL 2014003286A1 CL 2014003286 A CL2014003286 A CL 2014003286A CL 2014003286 A CL2014003286 A CL 2014003286A CL 2014003286 A1 CL2014003286 A1 CL 2014003286A1
Authority
CL
Chile
Prior art keywords
abediterol
asthma
treatment
pharmaceutical composition
dry powder
Prior art date
Application number
CL2014003286A
Other languages
English (en)
Spanish (es)
Inventor
Miquel Serra Gonzalo De
Ruiz Sandrine Allain
Nunez Beatriz Seoane
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003286(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CL2014003286A1 publication Critical patent/CL2014003286A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2014003286A 2012-05-31 2014-11-28 Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica. CL2014003286A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382221.5A EP2668941A1 (en) 2012-05-31 2012-05-31 Novel dosage form and formulation of abediterol
US201261660003P 2012-06-15 2012-06-15

Publications (1)

Publication Number Publication Date
CL2014003286A1 true CL2014003286A1 (es) 2015-02-20

Family

ID=46317311

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003286A CL2014003286A1 (es) 2012-05-31 2014-11-28 Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica.

Country Status (29)

Country Link
US (2) US20150140099A1 (OSRAM)
EP (2) EP2668941A1 (OSRAM)
JP (1) JP6272836B2 (OSRAM)
KR (2) KR20180104197A (OSRAM)
CN (1) CN104394852A (OSRAM)
AR (1) AR091233A1 (OSRAM)
AU (1) AU2013269565B2 (OSRAM)
BR (1) BR112014029735A2 (OSRAM)
CA (1) CA2871358C (OSRAM)
CL (1) CL2014003286A1 (OSRAM)
CO (1) CO7141434A2 (OSRAM)
CR (1) CR20140540A (OSRAM)
DO (1) DOP2014000271A (OSRAM)
EA (1) EA201401354A1 (OSRAM)
EC (1) ECSP14028814A (OSRAM)
HK (1) HK1203149A1 (OSRAM)
IL (1) IL235831B (OSRAM)
IN (1) IN2014DN08672A (OSRAM)
MX (1) MX2014014350A (OSRAM)
MY (1) MY184654A (OSRAM)
NI (1) NI201400139A (OSRAM)
NZ (1) NZ701261A (OSRAM)
PE (1) PE20150171A1 (OSRAM)
PH (1) PH12014502662A1 (OSRAM)
SG (3) SG11201407110QA (OSRAM)
TW (1) TWI610690B (OSRAM)
UY (1) UY34838A (OSRAM)
WO (1) WO2013178742A1 (OSRAM)
ZA (1) ZA201407405B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150224197A1 (en) * 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2015193631A1 (en) * 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
ES2964913T3 (es) 2018-05-22 2024-04-10 Bard Inc C R Sistema de cateterización
EP4614117A3 (en) 2018-08-10 2025-10-22 C. R. Bard, Inc. Automated urine-output-measurement systems and methods thereof
US12083261B2 (en) 2020-06-05 2024-09-10 C. R. Bard, Inc. Automated fluid output monitoring
US12055249B2 (en) 2020-07-21 2024-08-06 C. R. Bard, Inc. Automatic fluid flow system with retractable connection
US12408853B2 (en) 2020-12-17 2025-09-09 C. R. Bard, Inc. Smart bag to measure urine output via catheter
US12364423B2 (en) 2020-12-21 2025-07-22 C. R. Bard, Inc. Automated urinary output-measuring systems and methods
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system
US12246146B2 (en) 2020-12-23 2025-03-11 C. R. Bard, Inc. Automated weight based fluid output monitoring system
US12446813B2 (en) 2021-08-23 2025-10-21 C. R. Bard, Inc. Automated urine output system for attachment to hospital bed
WO2025151671A1 (en) * 2024-01-12 2025-07-17 Texas Tech University System Compositions and methods for treating diet-induced obesity and associated metabolic disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ES2113889T3 (es) 1990-09-26 1998-05-16 Pharmachemie Bv Dispositivos inhaladores provistos de un deposito para varias dosis de producto de inhalacion, dispositivo de transporte y camaras de turbulencia.
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
CN1325129C (zh) 1995-06-21 2007-07-11 Meda制药有限及两合公司 带整体计量装置的药筒和药粉吸入器
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2005263486B2 (en) 2004-07-16 2011-05-12 Astrazeneca Ab Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Also Published As

Publication number Publication date
AU2013269565B2 (en) 2017-07-20
ECSP14028814A (es) 2015-12-31
EP2854771A1 (en) 2015-04-08
TW201347789A (zh) 2013-12-01
CA2871358C (en) 2020-09-29
MY184654A (en) 2021-04-14
SG11201407110QA (en) 2014-12-30
DOP2014000271A (es) 2015-02-27
HK1203149A1 (en) 2015-10-23
ZA201407405B (en) 2015-11-25
PE20150171A1 (es) 2015-01-31
CN104394852A (zh) 2015-03-04
IN2014DN08672A (OSRAM) 2015-05-22
PH12014502662A1 (en) 2015-02-02
MX2014014350A (es) 2015-03-03
CO7141434A2 (es) 2014-12-12
JP6272836B2 (ja) 2018-01-31
NI201400139A (es) 2015-12-10
TWI610690B (zh) 2018-01-11
IL235831A0 (en) 2015-01-29
WO2013178742A1 (en) 2013-12-05
KR20150018526A (ko) 2015-02-23
NZ701261A (en) 2016-08-26
EA201401354A1 (ru) 2015-05-29
JP2015519356A (ja) 2015-07-09
KR20180104197A (ko) 2018-09-19
SG10201913424SA (en) 2020-03-30
IL235831B (en) 2020-09-30
BR112014029735A2 (pt) 2017-06-27
AU2013269565A1 (en) 2014-10-30
SG10201609119VA (en) 2016-12-29
US20160303108A1 (en) 2016-10-20
CR20140540A (es) 2015-01-16
CA2871358A1 (en) 2013-12-05
UY34838A (es) 2014-03-31
AR091233A1 (es) 2015-01-21
US20150140099A1 (en) 2015-05-21
EP2668941A1 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
CL2014003286A1 (es) Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica.
IL269054A (en) A pharmaceutical preparation containing tesimaltone for use in the treatment of 24-NON
BR112013016299A2 (pt) artigo abrasivo; e método para formar o mesmo
IL228925A0 (en) Benzothiazole compounds and their pharmaceutical use
BRPI1011721A2 (pt) formulações em pó seco e métodos para tratar doenças pulmonares.
CO6900138A2 (es) Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
HRP20180838T1 (hr) Formuliranje deksmedetomidina u obliku predsmjese
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
IL231951B (en) pam3cys-like stimulants and their use for the preparation of preparations
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
HUE049217T2 (hu) Szövetkárosodás és fibrózis enyhítése LTBP4 elleni ellenanyaggal
BR112012032330A2 (pt) formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
CL2014001966A1 (es) Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.
BR112014030044A2 (pt) uma composição na forma de uma dispersão compreendendo uma lignina , um método para a manufaturação da mesma e utilização da mesma
BR112015002706A2 (pt) niclosamida e seus derivados para uso no tratamento de tumores sólidos
CL2014002471A1 (es) Uso de un derivado de pirazol en el tratamiento de las exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica.
BR112014020992A2 (pt) Composto,uso de composto na fabricação de um medicamento e composição farmacêutica
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
PL2660161T3 (pl) Konfekcjonowanie suszonych liści w hermetycznych kapsułkach
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.
CL2014000792A1 (es) Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio